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Abstract
Investigators using anti-EpoR antibodies for immunoblotting and immunostaining have reported erythropoietin receptor (EpoR) expression in nonhematopoietic tissues including human tumors.
However, these antibodies detected proteins of 66 to 78 kDa, significantly larger than the predicted molecular weight of EpoR (56 to 57 kDa). We investigated the specificity of these antibodies and showed that they all detected non-EpoR proteins. C-20 detected 3 proteins in tumor cell lines (35, 66 , and 100 kDa). Sequences obtained from preparative gels had similarity to the C-20-immunizing peptide. The 66-kDa protein was a heat shock protein (HSP70) to which antibody binding was abrogated in peptide competition experiments. Antibody M-20 readily identified a 59-kDa EpoR protein. However, neither M-20 nor C-20 was suitable for detection of EpoR using immunohistochemical methods. We concluded that these antibodies have limited utility for detecting EpoR. Thus, reports of EpoR expression in tumor cells using these antibodies should be viewed with caution. in these studies detected 66-to 78-kDa proteins; however, the mature form of human EpoR has a calculated molecular weight of between 56 and 57 kDa. This discrepancy in size suggested that these antibodies cross-reacted with non-EpoR proteins. We therefore examined the specificity of anti-EpoR antibodies used in those studies.
Materials and methods

Cell culture and treatments
The MCF-7, 769-P, SH-SY5Y, HeLa, and Caki-2 cell lines from breast, kidney, brain, cervix, and kidney tumors, respectively, were obtained from the American Type Culture Collection (ATCC).
The megakaryoblastic leukemia cell line, UT-7/Epo, 13 was a gift from Dr Norio Komatsu, Jichi
Medical School, Minamikawachi, Japan. The murine leukemia cell line, 32D/Epo, required Epo for growth.
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Antibodies
We tested four commercially available rabbit polyclonal anti-peptide anti-EpoR antibodies 
Gene constructs
Tagged versions of EpoR contained an eight-amino acid N-terminal FLAG sequence attached to full-length EpoR (FLAG-EpoR) or to EpoR with the C-terminal 40 amino acids deleted (FLAGEpoR Δ40). COS-7 cells were transiently transfected with pcDNA3.1 containing these constructs or with pcDNA3.1 only, using Lipofectamine 2000 (Invitrogen).
Immunoblotting and peptide blocking studies
Cells were sonicated in 50 mM Tris-HCl (pH 7.2), 150 mM NaCl, 1% Triton X-100, 0.1% sodium deoxycholate, 1x complete protease inhibitor cocktail (Roche Applied Science; Indianapolis, IN), only.
For personal use at PENN STATE UNIVERSITY on February 21, 2013. bloodjournal.hematologylibrary.org From 100 μg/mL Pefabloc (Roche), and 10 μg/mL pepstatin. Reduced and denatured proteins were resolved by SDS-PAGE, transferred to PVDF membranes, blocked with 5% milk, and incubated with primary antibody. The secondary antibody was either anti-mouse or anti-rabbit conjugated to horseradish peroxidase (Amersham Biosciences; Piscataway, NJ). ECL-Plus (Amersham) was used for detection. Imaging was done using Hyperfilm (Amersham) and an X-ray developer. For blocking experiments, C-20 was preincubated with peptides and the immunoblots were processed as described. Peptides were synthesized based on the sequence 
Sequence analysis of proteins bound by C-20
Proteins immunoprecipitated by C-20 from UT-7/Epo cells were separated by SDS-PAGE, excised from the gel, reduced and carboxyamidomethylated, and subjected to overnight tryptic in-gel digestion as described (http://donatello.ucsf.edu/ingel.html). Peptides were separated by HPLC and analyzed by LC-MS/MS on a Thermo Finnigan LCQ DECA XP. Peptide sequences determined from MS/MS fragment ion spectra were searched against a non-redundant database to identify full-length proteins. Protein sequences that had at least a 5-amino acid identity to the C-20-immunizing peptide (C-20p) were analyzed further.
Results and Discussion
We performed a literature search on EpoR expression in tumors and identified 4 commercially For
20 was preincubated with a 5-fold mass excess of M-20-immunizing peptide (M-20p), staining was absent in both wild-type and knockout tissues ( Figure 2B,E) , suggesting the M-20 staining was due to cross-reactivity to non-EpoR protein(s). As expected, no staining was observed with IgG control antibodies ( Figure 2C,F) .
C-20 has also been used extensively to detect EpoR in tumor cells using immunohistochemistry methods, and investigators have reported that EpoR is overexpressed in tumor cells. [2] [3] [4] [5] [6] [10] [11] [12] Using C-20, we observed similar intensities of staining in UT-7/Epo, MCF-7, and 769-P cells that contained high, moderate, and undetectable levels of EpoR respectively, indicating that C-20 has insufficient specificity to determine EpoR expression. Cell staining was eliminated by preincubating C-20 with C-20p ( Figure 2H,K,N) , and no staining was observed with IgG control antibody ( Figure 2I ,L,O). Therefore, these controls do not validate the use of C-20 for immunohistochemistry.
In conclusion, this study shows that only M-20 is suitable for detection of the 59-kDa EpoR by immunoblotting, and none of the antibodies are suitable for detection of EpoR by immunohistochemistry. Thus, studies alleging EpoR expression using these antibodies should be interpreted with caution. 
